raltegravir-Dibromo impurity

Raltegravir-Dibromo impurity is a structurally related API impurity arising from bromination of the aromatic moiety in the parent drug raltegravir. It features a substituted naphthyridine core with two bromine atoms appended to the phenyl ring of the 5-methylisoxazol-3-yl group, altering the electronic and steric properties of the molecule. This impurity retains the pyrimidine and cyclopropyl functionalities characteristic of raltegravir but exhibits distinct chromatographic and spectroscopic profiles due to bromine incorporation. It serves as a critical HPLC reference standard for quantifying brominated degradation pathways in raltegravir formulations.